Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial

Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease

(2021) Konstantinos I. Avgerinos et al.   AGEING RESEARCH REVIEWS

“LRRK2: Autophagy and Lysosomal Activity”

(2020) Marta Madureira et al.   Frontiers in Neuroscience

Nucleic Acid–Based Therapeutics for Parkinson’s Disease

(2019) Masayuki Nakamori et al.   Neurotherapeutics

Cardiolipin Promotes Pore-Forming Activity of Alpha-Synuclein Oligomers in Mitochondrial Membranes

(2019) Stephanie Ghio et al.   ACS Chemical Neuroscience

Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model

(2019) Michal Wegrzynowicz et al.   ACTA NEUROPATHOLOGICA

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau

(2019) Matthias Brendel et al.   Alzheimers Research & Therapy

Tau-induced mitochondrial membrane perturbation is dependent upon cardiolipin

(2019) Angelique Camilleri et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Multiple System Atrophy: Recent Developments and Future Perspectives

(2019) Wassilios G. Meissner et al.   MOVEMENT DISORDERS

A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson’s disease

(2019) Lena F. Burbulla et al.   Science Translational Medicine

Photophysics of diphenyl-pyrazole compounds in solutions and α-synuclein aggregates

(2018) Anne M. Reiner et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint

(2018) Christine Kaindlstorfer et al.   JOURNAL OF ALZHEIMERS DISEASE

Movement disorder society criteria for clinically established early Parkinson's disease

(2018) Daniela Berg et al.   MOVEMENT DISORDERS

The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease

(2018) Diana L. Price et al.   Scientific Reports

Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy

(2018) Antonio Heras-Garvin et al.   MOVEMENT DISORDERS

α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies

(2017) Yvette C Wong et al.   NATURE MEDICINE

Diagnosis and management of dementia with Lewy bodies

(2017) Ian G. McKeith et al.   NEUROLOGY

Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies

(2015) Jens Wagner et al.   ACTA NEUROPATHOLOGICA

Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to α-synuclein aggregates

(2015) Andreas A. Deeg et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset

(2014) Johannes Levin et al.   ACTA NEUROPATHOLOGICA

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease

(2013) Jens Wagner et al.   ACTA NEUROPATHOLOGICA

Second consensus statement on the diagnosis of multiple system atrophy

(2008) S. Gilman et al.   NEUROLOGY